| 2.47 -0.05 (-1.98%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.02 | 1-year : | 3.23 |
| Resists | First : | 2.59 | Second : | 2.76 |
| Pivot price | 2.52 |
|||
| Supports | First : | 2.29 | Second : | 1.91 |
| MAs | MA(5) : | 2.5 |
MA(20) : | 2.5 |
| MA(100) : | 2.19  |
MA(250) : | 1.59 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 32.4 |
D(3) : | 35.9 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 3.38 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MBOT ] has closed above bottom band by 21.9%. Bollinger Bands are 67.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.55 - 2.57 | 2.57 - 2.59 |
| Low: | 2.42 - 2.44 | 2.44 - 2.45 |
| Close: | 2.44 - 2.47 | 2.47 - 2.5 |
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Wed, 09 Jul 2025
Microbot Medical Secures China Patent for LIBERTY System, Eyes Q3 2025 US Launch - Insider Monkey
Tue, 08 Jul 2025
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting - Stock Titan
Mon, 30 Jun 2025
Microbot Medical® Added to the Russell Microcap® Index - GlobeNewswire
Wed, 25 Jun 2025
Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth - Yahoo Finance
Tue, 17 Jun 2025
Microbot Medical's Surgical Robot Gets Crucial China Patent, Eyes 2.9M Annual Procedures - Stock Titan
Tue, 17 Jun 2025
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 38 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 8,060 (K) |
| Shares Short P.Month | 6,780 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.1 % |
| Return on Equity (ttm) | -66.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -3.86 |
| PEG Ratio | 0 |
| Price to Book value | 2.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|